Veterinary Infusion Pump Market to Surpass US$ 119.27 Million by 2025

The Global Veterinary Infusion Pump Market, by Product Type (Syringe Infusion Pump and Large-Volume Infusion Pump), by End User (Veterinary Hospitals and Veterinary Clinics) was valued US$ 76.89 million in 2017 and is projected to exhibit a CAGR of 5.6% over the forecast period (2017 - 2025) as highlighted in a new report published by Coherent Market Insights. Technological advancement by market players coupled with rising awareness regarding pet care are the major factors driving growth of the global veterinary infusion pump market over the forecast period.

Veterinary infusion pump delivers controlled amount of fluid and medications into the bloodstream over a period of time. Increasing prevalence of cancer along with rise in relapsed cancer rates indicates a need to adopt approved novel immunotherapies and targeted therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the veterinary infusion pump market growth. Hence, the manufacturers are involved in the launches of innovative products in the market. For instance, Vet Pro SP 3000 by Caesarea Medical Electronics for vet can provide accurate small dose and linear infusions. Furthermore, the device has a special feature of drug volume detection, which makes it easy and quick to set up an infusion for any animal.

Furthermore, increasing number of manufactures in the market offering veterinary pumps are driving manufacturers to develop innovative devices. For instance, BodyGuard 121 Twins for vet by Caesarea Medical Electronics allows user to set up fast high volume rapid infusions by mixing two different infusion solutions for an animal or by infusing to two different animals from one device.

Moreover, the rise in hospital admission rate due to obesity is expected to propel demand for veterinary infusion pumps market. According to the Association for Pet Obesity Prevention (APOP), in U.S.  54 percent dogs and 59 percent of cats were overweight or obese in 2016, the number of which increased to 56 percent dogs and 60 percent cats in 2017.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1689

Furthermore, manufacturers are focused on the development of infusion pumps especially for veterinary clinics, which is expected to boost the demand for veterinary infusion pump from clinics across the globe. For instance, Heska developed HESKA VET/IV 2.2 Infusion Pump for clinical use, whose calibration is available for Abbott Series A and B, Baxter ACT 5435s Henry Schein UniverSet. Its low weight (2.6 pounds) and compact structure makes it easy to carry and requires less space.

Key takeaways of the Veterinary Infusion Pump Market:

• The global veterinary infusion pump market is expected to expand at a CAGR of 5.6% during the forecast period (2017 – 2025), owing to increasing prevalence of disability among geriatric population.
• Large Volume Infusion Pump segment holds a major market share in product type, due to technical advancements and innovations by the manufacturers.
• Furthermore, the manufacturers are involved in innovation with the products such as HESKA VET/IV 2.2, and Vet Pro SP 3000 to make them more user friendly and cost effective. The cost effective nature of this product is expected to boost market revenue over the forecast period.
• Some of the major players operating in global veterinary infusion pump market are B. Braun Melsungen AG, Heska Corporation, Q Core Medical Ltd., Burtons Medical Equipment Ltd., DRE Medical, Inc., Grady Medical, Promed Group Co., Ltd., and SAI Infusion Technologies.

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Recombinant Protein Market to Surpass US$ 593.4 Million Threshold by 2025 Globally

The global recombinant protein market by Product Type (Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, and Others), By Application (Drug Discovery & Development, Biopharmaceutical Production, Basic Research, and Others), By End User (Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 347.2 million in 2016 and is projected to exhibit a CAGR of 6.2% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Availability of wide number of innovative recombinant proteins from various sources such as human and animal, lack of suitable alternative for basic protein related therapies research, and increasing demand for biopharmaceutical products is expected to fuel growth of the recombinant protein market.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1516

Manufacturers are involved in collaborations and acquisitions for drug discovery and development purposes. For instance, in 2017, Crown Bioscience (CBI), Inc. entered into collaboration with Jiangsu Qyun Bio-Pharmaceutical Co. Ltd. to develop CTLA-4 antibody. Moreover, in 2016, CBI acquired PreClinOmics, Inc., an in Vivo preclinical company, which specializes in early research in cardiovascular and metabolic disease and in 2016 CBI introduced six new recombinant cell lines GITR, ICOS, CD137, CTLA-4, OX40, and RANK immune checkpoints and receptors for biological studies, drug discovery, and development. In 2012, ProSpec-Tany Technogene Ltd. and LifeMap Sciences, Inc.—a wholly owned subsidiary of BioTime, Inc.—announced definitive agreement to offer 1,000 recombinant proteins and antibodies, to be used for stem cell research, drug discovery, and development biology. In 2014, BPS Bioscience, Inc. announced the introduction of 13 different mutant EZH2 complexes and two new assay kits for screening inhibitors of mutant EZH2.

Key players in the company are focusing on expanding their geographic presence, in order to enhance their market share. For instance, in 2016, Sigma Aldrich Company Ltd. established nine new M Lab Collaboration Centers in Asia, North America, Europe, and Latin America for its life science business. The centers are expected to boost growth of its recombinant protein business. Manufacturers participate in international and national conferences to promote their products. For instance, in 2014, Novoprotein Scientific, participated in AAPS National Biotechnology Conference, which was dedicated to recent developments of protein recombinants worldwide. In 2016, PeproTech, Inc. participated in conference on Advances in Stem Cells and Regenerative Medicine held at EMBL, Heidelberg, Germany, in 2017. Feldan Bio, Inc. and Elasmogen, a biopharmaceutical company, signed an exclusive partnership for the development of intracellular biologics in 2016. BioVision Inc. introduced Cas9 recombinant protein for genome editing in 2017. Cas9 protein of the CRISPR-Cas9 system is an RNA-guided DNA endonuclease enzyme, which helps in unwinding of genomic DNA complex.

Browse 39 Market Data Tables and 40 Figures spread through 151 Pages and in-depth TOC on Recombinant Protein Market by Product Type (Hormones, Growth Factors, Cytokines, Plasma Protein Factor, Recombinant Metabolic Enzymes, Immune Checkpoint Regulators, and Others), By Application (Drug Discovery & Development, Biopharmaceutical Production, Basic Research, and Others), By End User (Biopharmaceutical Companies, Academic & Research Institutes, Contract Research Organizations, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) - Global Forecast to 2025

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/recombinant-protein-market-1516

Key Takeaways of the Recombinant Protein Market:

• The global recombinant protein market is expected to exhibit a CAGR of 2% over the forecast period (2017–2025), owing to product launches by manufacturers such as BioVision, Inc., and HumanZyme, Inc.
• Growth of the recombinant protein market is driven by strong demand for applications such as drug discovery & development and basic research
• Hormones segment is expected to exhibit high growth over the forecast period, owing to applications in research and development of therapies for various metabolic disorders such as diabetes and others
• Asia Pacific region is expected to exhibit strong growth over the forecast period, due to activities such as research, and collaborations in the region. For instance, Amgen, Inc. collaborated with Simcere Pharmaceutical Group, a China-based company, to develop four biosimilars for the Chinese market in 2017.
• Major players operating in the global recombinant protein market include Crown Bioscience, Inc., ProSpec Tany TechnoGene, Ltd., BPS Bioscience, Inc., Sigma Aldrich Company Ltd., Novoprotein Scientific, PeproTech, Inc., Feldan Bio, Inc., BioVision, Inc., HumanZyme, Inc., and GenScript Biotech Corporation

About CMI

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Tuberculosis Vaccine Market - Latest Advancements & Market Outlook 2018 to 2026

Tuberculosis (TB) is a highly contagious disease caused by the bacterium known as Mycobacterium tuberculosis and is mostly spread through person to person contact. It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of TB. Clinical symptoms and signs of TB include fever, night sweats, cough, weight loss, hemoptysis (coughing up blood-stained sputum), fatigue, chest pain, and shortness of breath. Depending upon the symptoms, TB may be classified as pulmonary TB, subcutaneous TB or military TB. Depending on the resistance it shows, TB may be multidrug resistant TB or extended drug resistant TB. Diagnosis of tuberculosis can be carried out using skin test, polymerase chain reaction test or interferon-gamma release assays. Initial treatment regime for active TB includes drugs such as ethambutol, pyrazinamide, isoniazid, and rifampicin. Although currently no TB vaccine is approved commercially, children are vaccinated with BCG vaccine as a part of precautionary measure. However, BCG vaccine has limited utility and variable efficacy in both adults and children. Many TB vaccines are under the stage of clinical development, which are expected to reach the market in the near future.

To get detailed table of content (ToC), please click: https://www.coherentmarketinsights.com/insight/request-sample/1602

Tuberculosis Vaccine Market Dynamics

Tuberculosis account for the highest amount of death caused due to infectious disease across the globe. According to the World Health Organization (WHO) factsheet 2018 on TB, 10.4 million people fell ill with TB in 2016 and 1.7 million people with TB died in the same year. More than 95% of TB deaths occur in low- and middle-income economies. Deaths caused due to TB also includes death of 0.4 million people infected with HIV. Such high number of patients across the world confirms the enormity of disease and urgent requirements for vaccines worldwide. Therefore, the launch of tuberculosis vaccine would gain significant revenue and in turn, would propel the market growth. According to a global report on tuberculosis vaccine in 2018, TB costs around US$ 21 billion annually to global economy. Another important impetus to tuberculosis vaccine market would be current complex drug regime and resistance TB has created to this drug regime. TB patient has to take more than 2-3 drugs for prolonged time period of 6 months in order to suppress the infection. Often this results in the poor patient compliance and eventually leads to drug resistance incidence which further deteriorate the TB. According to WHO, there were nearly 600,000 new cases with resistance to rifampicin antibiotic, which was the most effective first-line drug in 2017, of which around 490,000 had MDR-TB globally. If effective steps won’t be taken by 2050, MDR-TB alone could cost the world US$ 16.7 trillion as per global report on tuberculosis vaccine 2018. Drug toxicity due to high daily dose and prolonged treatment is another concern with current TB drugs. Although the cost of TB drug is not much of concern in developing economies due to government support and free medication, it is a matter of concern in developed countries such as the U.S. and Europe. Increased recognition of TB’s fatality by intergovernmental organization and national government would prosper funding for TB vaccine research. Increased research and development activities for development of vaccine against TB by companies and intergovernmental organizations is expected to boost growth of tuberculosis vaccine market. For instance, Aeras is an NGO, which supports TB vaccine development and has helped develop 9 TB vaccine candidates and conducted over 35 Phase 1-2b clinical trials.

Tuberculosis Vaccine Market - Regional Insights

TB is most prevalent in middle and low income economies in Asia Pacific and Africa and therefore, these regions would represent greatest opportunity for the potential TB vaccine. According to the World Health Organization factsheet 2018 on TB, countries such as India, China, Indonesia, Philippines, Pakistan, Nigeria, and South Africa account for around 64% of the total TB deaths. Another risk factor for these regions is the high number of HIV positive population living in this region. Around 40% of deaths among HIV-positive people were due to TB in 2016 as per WHO. Tuberculosis vaccine could prove most beneficial for these regions and in turn, would drive growth of tuberculosis vaccine market. Government initiatives and international support to curb TB incidence would speed up the vaccine development and also would support access for such vaccines. India, which accounts for half a million global TB deaths has launched National Strategic Plan (NSP) for TB Elimination 2017-2025 to combat TB. India also formed India TB Research Consortium to boost TB vaccine and medication research. Developed regions such as North America accounts for significant number of TB patients. According to the Centre for Disease Control, a total of 9,093 TB cases were reported in the U.S. in 2017. MDR-TB and XDR-TB accounted for approximately US$ 160,000 and US$ 513,000 respectively for treatment of each patient. Effective vaccine against TB would gain significant traction in countries such as the U.S.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1602

Tuberculosis Vaccine Market - Competitive Landscape

Many companies and research institutes are taking efforts to develop tuberculosis vaccine to combat TB. There are fourteen TB vaccines under clinical trials, out of which one investigational candidate named Vaccae from China is in phase three whereas three are in late phase 2. Most of the researches are carried out in academic and research places, which eventually would be transferred to commercial companies for effective distribution and access. Companies are also improving current BCG vaccines, in order to target TB by bringing recombinant vaccine product.

Some of the key players in the tuberculosis vaccine market include GlaxoSmithKline, Sanofi Pasture, Longcom Enterprise Ltd, Biofabri, Valneva plc, and Archivel Farma S.L.

Tuberculosis Vaccine Market Taxonomy:

On the basis of type of vaccine, the global tuberculosis vaccine market is segmented into:

• Viral Vector Vaccine
• Recombinant Protein Vaccine
• Recombinant BCG Vaccine
• Attenuated Vaccine
• Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Closed MRI Systems Market - Latest Advancements & Market Outlook 2018 to 2026

Magnetic resonance imaging (MRI) is a non-invasive medical test that uses powerful magnetic field, radio waves, and a computer to produce detailed virtual image of internal organs of the body. Closed MRI systems have a tube-like tunnel with magnetic field of around 1.5 to 3.0 tesla or above to generate detailed image of the organs. Closed MRI system is used in screening and diagnosis of brain, cardiac, spine, breast or abdominal abnormalities. According to European Magnetic Resonance Forum (EMRF) Foundation, the US sale of MRI machine in 2014 / 2015 was approximately 11,500 MRI systems for which one quarter is open system and rest are closed systems. The closed MRI system market is expected to witness growth, owing to its advantages over conventional open MRI and increasing incidence of brain and spinal injuries.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1610

Closed MRI Systems Market Drivers

Advantages of using closed MRI systems over open MRI systems is expected to be a major factor for growth of the market. Closed MRI systems have field strength of 1.5 Tesla and can reach up to 3.0 Tesla, which can give four to five times clearer imaging results as compared to open MRI system. This advantage of wide range of field strength has led to increasing use of these systems in lesion detection in multiple sclerosis, nerve visibility for brachial plexus, anatomic structures in the wrist or diagnostic accuracy for hepatic metastases.

Increasing awareness about benefits of MRI over X-ray and other imaging techniques using harmful radiation is also expected to propel growth of closed MRI system market in the forecast period. For instance, over the period of January 2016 to January 2017, 3,234,690 patients underwent MRI diagnosis in England. Moreover, increasing number of MRI machine installation is expected to enhance the closed MRI system market growth. For instance, in March 2018, G. Greene Construction Co. installed a Siemens 3T MRI at Boston Children’s Hospital. Furthermore, Cape Breton Regional Hospital installed a new MRI unit, in March 2018. Increasing incidences of spinal and brain injuries is also expected to create a conducive environment for growth of the closed MRI market. For instance, according to 2017 Spinal Cord Injury factsheet of National Spinal Cord Injury Statistical Center (NSCISC), the annual incidence of spinal cord injury in the U.S. is 54 cases per million or about 17,500 new cases each year.

Closed MRI Systems Market Restraint

Owing to its closed structure, several claustrophobic patients suffer from panic attacks during MRI diagnosis. For instance, according to factsheet of 2014 Health Research Funding Organization, up to 13% of the patients suffer from panic attacks due to claustrophobia during MRI diagnosis. This is expected to be a major restraining factor for growth of the market.

Furthermore, high cost of closed MRI system is expected to hinder growth of the closed MRI systems market. Moreover, lack of skilled professionals to handle the systems in emerging countries is a major challenge for growth of the closed MRI system market. In 2016, according to the prediction of Global Health Workforce Labor Market Projections for 2030, global demand for health workers will rise to 80 million workers, double the current (2013) while the supply of health workers is expected to reach 65 million over the same period, resulting in a worldwide net shortage of 15 million health workers. According to World Health Organization (WHO) in 2016, India is lacking with 500,000 doctors. According to the recent study findings by Public Health Foundation of India for Ministry of Health and Family Welfare in 2015, radiography and imaging professionals alone accounts for 88.7% of skill gap out of 97.9% across various health workforce categories, amounting to a huge shortage of medical laboratory technicians.

Closed MRI Systems Market - Regional Analysis

Based on geography, the closed MRI system market has been segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. Europe holds the dominant position in the closed MRI system market over the forecast period, owing to high adoption of closed MRI as compared to open MRI. For instance, according to European Magnetic Resonance Forum (EMRF) Foundation, open systems are mostly sold in the U.S., and the market share of open system is limited in Europe. This is creating a demand for closed MRI systems usage in the diagnosis in Europe.

Closed MRI Systems Market – Competitive Analysis

Key players in the closed MRI systems market are Hitachi, Siemens Healthineers, Canon Medical Systems, GE Healthcare, Philips, Aspect Imaging, Bruker, Aurora Imaging Technology and Esaote S.P.A. Various strategies adopted by key players in closed MRI system market are mergers and acquisitions. For instance, in October 2015, Toshiba acquired medical imaging application developer, Olea Medical. The acquisition is expected to enhance the MRI business of the company by offering Olea’s software for advanced post-processing and image analysis as well as the company’s relationships and agreements with research institutions and customers will aid the MRI business.

Closed MRI Systems Market - Taxonomy

By Strength of Magnetic Field

• 5 Tesla,
• 0 Tesla
• Others

By Application

• Brain
• Spine
• Cardiac
• Breast
• Abdominal

By End Users

• Hospitals
• Diagnostic Centers
• Research Institutes

By Region

• North America
• Europe
• Latin America
• Middle East
• Asia Pacific
• Africa

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Vascular Endothelial Growth Factor Antibodies Market Growth – Key Futuristic Trends and Competitive Landscape 2026

Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels, and as a bypass for a blocked vessel. However, overexpression of VEGF often culminates into fatal disease such as cancerous cells. As solid tumors require additional blood supply in order to keep functioning, the overexpression of VEGF serves that purpose through angiogenesis. VEGF family has five members such as VEGF-A, VEGF-B, VEGF-C, VEGF-D, and Placenta Growth Factor (PGF). Out of these growth factors, VEGF-A is responsible for angiogenesis and processes associated with endothelial cells. VEGF-A binds to VEGF receptors on the endothelial cells, which triggers a tyrosine kinase pathway leading to angiogenesis. VEGF-A has been found to be associated with poor prognosis in various cancers, diabetic retinopathy, and age-related macular degeneration. Therapeutic agents are developed to inhibit the transduction pathways of vascular endothelial growth factor (VEGF). Drugs such as monoclonal antibodies against VEGF and tyrosine kinase inhibitors inhibit the angiogenesis process and disease progression.

Request a sample to stay abreast on the key trends impacting this market: https://www.coherentmarketinsights.com/insight/request-sample/1614

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Drivers

Rising prevalence of diseases such as cancer and macular degeneration is expected to boost growth of the market over the forecast period. According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths. Novel therapies such as monoclonal antibodies and angiogenesis inhibitors are highly specialized targeted therapies, which directly targets the cancerous cells. The preference for targeted therapies is rising, owing to the advantages (lesser side effects) offered by targeted therapies over conventional therapies such as chemotherapy. Furthermore, robust pipeline of VEGF antibodies is expected to boost the market growth over the forecast period. For instance, Brolucizumab (Alcon) is in phase 3 clinical trials, Abicipar (Allergan Plc) is in phase 3 trials, and RG7716 (Genentech) is in phase 2 trials, all indicated for age-related macular degeneration. Moreover, Tecentriq manufactured by Roche received the U.S. FDA priority review status to treat people with metastatic non-squamous non-small cell lung cancer in May 2018. Therapies already present in the market have shown improved clinical outcome in cancer as well as age-related macular degeneration (AMD). For instance, Lucentis, as well as Avastin have shown significant improvement in medical outcomes in associated indications such as cancer. These therapies have spurred the interest of manufacturers to further carry out research in this category, which is shown in terms of number of agents present in the pipeline. Blockbuster drugs such as Avastin and Lucentis allow manufacturers to invest in research and development of such therapies, in order to generate the revenues later on while providing the benefits to patients as well. These factors are expected to foster growth of the market over the forecast period.

However, high costs of these medications, biosimilar research, and subsequent launches are expected to hamper the growth of the market. The U.S. Food & Drug Administration has already approved Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) in December 2017. Moreover, European Commission approved biosimilar to Avastin (bevacizumab) in January 2018.

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Insights

On the basis of region, North America and Europe are expected to show significant growth in the vascular endothelial growth factor antibodies market over the forecast period. North America has the presence of leading manufacturers who are indulged in research and development of these therapies. Manufacturers such as Novartis (Europe) and Genentech have these therapies in pipeline and are expected to enter into the market over the forecast period. Asia Pacific region is expected to show modest growth, owing to high costs of these therapies and fairly low availability overall the region. Sophisticated insurance facilities such as Medicaid and Medicare are not present in the developing economies due to which patients cannot afford costly medical treatment in these regions. However, insurance facilities are expected to drive growth of the market in North America.

Key players operating in the vascular endothelial growth factor (VEGF) antibodies market include Genentech, Inc., Novartis, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd, and ThromboGenics, Inc.

Vascular Endothelial Growth Factor (VEGF) Antibodies Market Taxonomy 

The global vascular endothelial growth factor (VEGF) antibodies market is segmented on the basis of drug, route of administration, application, distribution channel, and geography.

By Drug -

• Avastin
• Tecentriq
• Cometriq
• Eylea
• Jetrea
• Cyramza
• Macugen
• Lucentis
• Others

By Route of Administration-

• Oral
• Intravenous
• Intravitreal
• By Application-
• Cancer
• Ophthalmology
• Others

By Distribution Channel-

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.